Strong YoY growth masked by QoQ softness, margin pressure; diversification strategy real but early-stage
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Hold
confidence 7/10
Grade B
Q1 numbers aligned with stated targets (+19.2%, +15% guidance). Margin miss (17.9% vs 18-21%) and QoQ softness were not highlighted, suggesting mixed transparency.
Cautiously Optimistic
next 1–2 quarters
Optimistic
multi-year
NRB delivered robust Q1 YoY growth (+19.2% revenue, +15.1% PAT) and launched an ambitious, funded diversification strategy (₹270 capex, MTR/Unitec/Corvette wins). But near-term is fragile: QoQ declined (revenue -0.7%, PAT -10.3%), OPM fell to 17.9% (below 18-21% target), and input cost headwinds (electricity, logistics, petroleum) are mounting. Execution risk on nascent verticals (aerospace, defense, data centers) is elevated; most order books are small relative to targets.
₹369.5 Cr
Revenue · +19.2% YoY₹37.8 Cr
Reported PAT · +15.1% YoYCompressing
Margins · vs guidance: MixedDid the claims hold up?
Revenue ₹370 Cr, profit ₹38 Cr, +19.2% YoY growth
METDelivered ₹369.5 Cr revenue, ₹37.8 Cr PAT, +19.2% YoY, +15.1% PAT YoY
Standalone PAT +31.7% YoY, EBITDA +21.7% YoY
METStandalone growth significantly outpaced consolidated (+15% PAT), confirming strong core business but portfolio drag
Margins between 18-20% targeted
MISSDelivered OPM 17.9%, NPM 10.1%; at low end of 18-21% prior guidance, below target
Strong momentum in Q1
OVERSTATEDYoY +19.2% but QoQ revenue -0.7%, PAT -10.3%; sequential softness despite annual strength
Cost management via VAVE and price increases
METOther expenses rose ₹10 crores (electricity, logistics, petroleum); management offsetting but headwinds evident
Earnings quality
What changed since the last call
Capex guidance
UpgradeRaised from ₹120 Cr (prior) to ₹270 Cr total; ₹60 Cr spent, ₹100 Cr ordered; rule: ₹100 capex → ₹130 sales
Nominated business pipeline
UpgradeIncreased from ₹800 Cr (prior) to ₹1,100 Cr; driven by GM Corvette (300k volume/year) + other automotive adjacency wins
Long-term revenue target
NeutralPrior ₹2,500 Cr by 2031; now 14.38% 12M CAGR extrapolates to ₹2,730 Cr. Management called ₹2,500 'too low', offered ₹3,000 as 'aspirational' but refused formal upgrade
EBITDA margin guidance
NeutralReaffirmed 18-20% on annual basis (prior 18-21%); Q1 came at 17.9%, management said cyclical, expects recovery
Cost headwinds
DowngradeOther expenses up ₹10 Cr QoQ to ₹102 Cr; electricity, logistics, petroleum-driven. Management using VAVE and price hikes to offset.
The Q&A
Analysts pressed hard on growth guidance (Varun Jain asked for ₹3,000 crore confirmation), capex justification (Apoorv queried ₹250→₹270 jump), and defense revenue timing (Shreya, Saloni sought specifics). Management deflected on near-term numbers, citing conservatism and annual vs quarterly guidance preference. Tone was confident but evasive on formal commitments, signaling reluctance to over-promise given execution risk on new ventures.
FY27 growth trajectory — Varun Jain, Dolat Capital
DodgedDeclined to commit. Cited 14.38% trailing 12-month CAGR → ₹2,730 Cr by 2031. Said ₹2,500 'too low', ₹3,000 'aspirational', prefers annual updates to avoid confusion.
Unitec JV capex & location — Varun Jain, Dolat Capital
AnsweredApril 2027 commissioning. ₹110 Cr investment (not capex), ₹130 Cr capacity. Moved location Hyderabad → Aurangabad for logistics/cost reasons; purchased partly ready facility to meet timeline.
Industrial segment path — Rajveer Singh, Vivek Investments
AnsweredIndustrial 14%, grew 34% YoY, up from 11% in prior years. Track only annually, not quarterly, due to seasonal variation.
EV bearing content — Rajveer Singh, Vivek Investments
PartialEV-agnostic strategy; 70% in applications common to ICE/hybrid/EV (chassis, transmission, steering). No pure-EV concentration risk. Refused to quantify bearing content delta.
Defense aerospace order book — Shreya, Serene Alpha
PartialMTR aerospace order book ₹25-30 Cr (later ₹30 + ₹20 regular defense = ₹50 total). Projected ₹300 Cr revenue, ₹90 Cr profit by 2031. FY27 'hard to predict'; Sukhoi-30 spherical bearing order is breakthrough (few global competitors).
Defense order book clarification — Saloni, Molecule Ventures
DodgedSeparated MTR aerospace (₹30) from regular defense (₹20) = ₹50 total. Prior guidance conflated verticals.
Data center market entry — Saloni, Molecule Ventures
PartialData center is NRB (not JV) initiative, still in R&D. Will announce when ready. Acknowledged opportunity is huge; competitors already entered.
Guidance growth rate mismatch — Saloni, Molecule Ventures
DodgedPrefer to be conservative. Use 12-month baseline (14.38% CAGR) to extrapolate; if that rate holds → ₹2,730 Cr. ₹2,500 'too low', ₹3,000 'aspirational'. Will give full update annually, not quarterly, to avoid confusion.
SNL Bearings merger — Sunil, Investor
AnsweredNo concrete merger plans. SNL has proprietary tech, own brand, serves price-sensitive segment. Allows NRB to focus on bigger things. SNL growing aggressively.
Other expenses spike — Shreyans, SG Securities
AnsweredElectricity, logistics, petroleum cost escalation. Offsetting with VAVE (value engineering) and price increases; all three levers in play simultaneously.
Capex progress — Apoorv, Whitestone Financial
AnsweredTotal ₹270 Cr (not ₹250). ₹60 Cr already spent, ₹100 Cr ordered/in process. Rule: ₹100 capex → ₹130 sales.
Margin sustainability — Samarth, Investor
AnsweredMargins 18-20% on annual basis (not quarterly). Time lags, cost escalations happen; must be flexible. Business model by design yields profitable engineering outcomes. Not a quarterly driver.
Mahant Tool talent retention — Samarth, Investor
AnsweredYes. Mr. Mallappa now leads aerospace-defense segment, integrated into NRB supply chain. Acquisition was partly to give him resources to scale dreams.
Lifetime nominated business — Varun Jain, Dolat Capital (follow-up)
AnsweredYes, increased ₹800 → ₹1,100 Cr. GM Corvette alone (300k peak volume/year) plus other wins drove jump. Land + partially ready building already purchased in Shendra (Aurangabad) for April 2027 commissioning.
Robotics/humanoid products — Rajveer Singh, Vivek Investments (follow-up)
AnsweredNRB makes 4,000 products, customized solutions provider. Works with OEMs on design; offers bearings + precision components tailored to their robots. No off-the-shelf; all engineered.
Guidance
FY27: No explicit target given. 12-month CAGR 14.38% → ₹2,730 Cr by 2031.
LowManagement refused quarterly/annual FY27 commitment; deflected to trailing 12M extrapolation. Implies ~15-16% FY27 growth at best if annualized.
FY31: ₹2,500 Cr (prior), ₹2,730 Cr (12M extrapolated), ₹3,000 Cr (aspirational).
MediumCalled ₹2,500 'too low'; won't formally raise to avoid quarterly confusion. Effective guidance is ₹2,730-3,000 range.
EBITDA 18-20% on annual basis (prior 18-21%).
MediumQ1 delivered 17.9% OPM, below range. Management reframed as cyclical, seasonal variation between quarters.
Margin improvement via structural action, capacity expansion, diversification.
MediumNew verticals (aerospace, EV, industrial, defense) positioned as higher-margin. But execution risk is elevated; most nascent.
Total ₹270 Cr over medium term (raised from ₹120 Cr/year).
High₹60 Cr spent, ₹100 Cr ordered/in process, ₹110 Cr for Unitec JV. Rule: ₹100 capex → ₹130 sales.
Unitec JV ₹110 Cr investment, ₹130 Cr capacity, April 2027 commissioning.
HighLand purchased, partially ready building. Moved Hyderabad → Aurangabad for logistics/cost optimization.
Risks the call surfaced
Input cost inflation
MediumOther expenses jumped ₹10 Cr (₹92 → ₹102) this quarter. Management offsetting with VAVE and price hikes, but if input costs accelerate faster, margins will compress below 18-20% target.
Execution risk on diversification
HighMTR aerospace order book ₹25-30 Cr despite ₹300 Cr revenue target by 2031 (10x gap). Data center in R&D. Robotics/humanoid nascent. GM Corvette hasn't started production. If ramp is slower than assumed, FY31 ₹2,730-3,000 Cr target will miss.
Sequential momentum loss
MediumQ1 sequential decline signals either strong prior-quarter comp, seasonality, or momentum loss. If Q2 also declines QoQ, narrative of 'strong momentum' will erode. Not highlighted in opening remarks; transparency concern.
Consolidated vs standalone divergence
LowNRB core (standalone) is outperforming; subsidiaries (SNL, MTR if already consolidated, others) are dragging. If subsidiary integration fails or SNL growth slows, overall group CAGR target will miss.
Guidance opacity / execution uncertainty
MediumAnalysts pressed on ₹3,000 Cr FY31 target (vs ₹2,500 Cr prior); management refused to formally raise, citing conservatism. This signals lack of confidence in near-term delivery or unwillingness to over-promise. Evasion on FY27 guidance also flags uncertainty.
Management
Score 7/10. Confident on strategy and market positioning; evasive on near-term financial commitments. Transparent on segment details (industrial 14%, EV-agnostic 70%) but deflected on formal guidance raises. Q&A showed willingness to engage but preference for annual vs quarterly updates suggests opacity risk. Track record solid on Q1 targets (revenue/PAT matched stated numbers, +19.2% YoY growth on track). Capex raised mid-call (₹120 → ₹270) shows ambition but also lack of forward planning clarity. Margin miss (17.9% vs 18-21% target) not prominently flagged; transparency gap.
1 · April 2027
Unitec JV industrial gearbox facility commissioned; ₹110 Cr investment, ₹130 Cr capacity
2 · 2027
BMW i steering launch; common across ICE/hybrid/EV, validates diversification thesis
3 · Q2–Q3 FY27
GM Corvette production ramp; US manufacturing facility first win, 300k peak volume potential
Execution risk on nascent verticals (aerospace, defense, data centers) is elevated; most order books are small relative to targets.
NRB Bearings Q1FY27: consol PAT +15% YoY (~9% ex one-off), NPM dips despite OPM gains
PAT +15.09% YoY · revenue +19.19% · margins compressing
₹369.53 Cr
+19.19% YoY
₹37.76 Cr
+15.09% YoY
10.07%
-0.2pp YoY
₹3.8
NRB Bearings' consolidated PAT for Q1 FY27 (quarter ended 30 June 2026) came in at ₹37.76 Cr, up 15.1% YoY from ₹32.81 Cr but down 10.3% QoQ from ₹42.09 Cr. Reported growth is flattered by a ₹2.65 Cr exceptional gain (insurance claim on the 2023 Waluj fire, sanctioned this quarter); stripping that out on an effective ~26.6% tax rate, adjusted PAT growth is a more modest ~9.2% YoY. Consolidated revenue rose a stronger 19.2% YoY to ₹369.53 Cr, though it was flat sequentially (-0.7% vs ₹371.98 Cr in Q4 FY26). Standalone PAT was ₹34.77 Cr on revenue of ₹319.89 Cr, with the roughly ₹50 Cr consolidated-standalone revenue gap coming from SNL Bearings, NRB Holdings UAE and the overseas step-down units.
Q1 FY-2027 vs prior quarters
The margin picture is mixed. Operating margin (EBITDA/revenue) expanded 65bps YoY to 17.23% on volume-led operating leverage, though it eased from 18.01% in Q4 FY26 and sits below management's own 18-21% guided band. Net margin, by contrast, compressed to 10.07% from 10.27% a year ago and 11.11% last quarter — other income fell 41.9% YoY to ₹5.47 Cr (from ₹9.41 Cr) and depreciation rose 41% YoY to ₹18.35 Cr as the capex cycle ramps, partly cushioned by a 30% YoY drop in finance costs.
The stock went into the print at ₹461.5, up 9.2% over the past month of trading.
What the summary numbers don't show
Consolidated EPS ₹3.80 (₹3.60 before the exceptional item) vs ₹4.27 in Q4 FY26 and ₹3.31 a year ago
Management guides for 10-14% growth in international business for FY27, supported by a capex plan of INR 120 crores for the year to address capacity bottlenecks. The company aims to sustain EBITDA margins between 18% and 21% through ongoing structural improvements. Long-term, NRB has a concrete goal of reaching INR 2,5
— This quarter: missed
Management issued no press release alongside this filing, so there is nothing fresh to grade beyond the last concall's guidance: sustaining EBITDA margins of 18-21% and 10-14% international-business growth for FY27, backed by a ₹120 Cr capacity capex plan. On margins the quarter sits just below the guided floor; the international-growth leg cannot be checked since NRB discloses a single 'Bearing' segment with no geography split. No verifiable street/consensus estimate for this quarter turned up in search, so vsStreet is unknown. The quarter's other developments — a ₹50 Cr corporate guarantee to HSBC for term loans at the new NRB Unitec (Mondial Group JV), and completion of the Mahant Tool Room acquisition (aerospace push) on 10 July 2026 with a further ₹30.5 Cr equity infusion — are balance-sheet/strategic moves rather than P&L drivers this quarter, but add to the capacity and diversification NRB will need to fund toward its own ₹2,500 Cr five-year revenue goal.
W1
OPM re-crossing management's 18-21% guided band — Q1 FY27 print at 17.23% sits below the floor
W2
International business growth pace against the 10-14% FY27 guidance — no segment-wise split disclosed this quarter to verify
W3
Deployment of the ₹120 Cr FY27 capacity capex and its drag on depreciation (already +41% YoY this quarter) against the operating leverage it's meant to deliver
Double-digit growth masks margin miss and execution risk
NRB posted strong 19.2% revenue growth year-on-year, but the quarter revealed sequential softness, margin compression below guidance, and a capex bet that's not yet paying off. The street noticed—the day-1 pop faded completely by day 5.
+19.2%
₹369.5 Cr delivered
-0.7%
Sequential softness
17.9%
vs 18-21% target
On the surface, NRB's Q1 FY27 looks like a headline win: revenue of ₹369.5 crores (+19.2% year-on-year), PAT of ₹37.8 crores (+15.1% YoY), and a capex plan doubled from ₹120 crores to ₹270 crores to fund expansion into aerospace, defense, and industrial bearings. But the quarter buried some uncomfortable truths—and the street's price reaction reveals it caught them.
What the quarter really was
The year-on-year numbers are genuine. The core business is growing, and standalone NRB (excluding subsidiaries) posted PAT growth of +31.7% year-over-year, significantly outpacing the consolidated +15.1%. That outperformance is critical: it says the operating business is firing on all cylinders, but the group's consolidated numbers are held back by subsidiaries lagging. Specifically, consolidated growth (+15.1%) lags standalone (+31.7%)—a ₹16-crore gap in PAT growth—suggesting that either SNL Bearings or other acquired entities (MTR, now integrated post-acquisition) are not yet contributing proportionately.
But flip to the quarter-on-quarter story, and the picture inverts. Revenue fell 0.7% sequentially, and PAT collapsed 10.3% quarter-on-quarter. Management didn't lead with this in the opening remarks—a meaningful omission. The sequential decline directly contradicts any "strong momentum" narrative. And it matters because it signals either seasonal weakness (plausible; automotive often softens in Q1) or the start of a trend. Q2 will clarify which.
The margin miss is the harder truth. Operating profit margin landed at 17.9%—at the low end of the 18-21% prior guidance and below the reaffirmed 18-20% annual target. Management deflected this as "cyclical" and "quarterly variation." Fair enough in isolation, but the root cause—other expenses jumped ₹10 crores quarter-on-quarter to ₹102 crores—is tangible: electricity, logistics, and petroleum cost escalation. Management said they're offsetting with value-engineering (VAVE) and price increases, but ₹10 crores in cost pressure on a ₹370-crore revenue base is a 2.7% hit. VAVE and pricing can't absorb that fast. So the margin miss is real, and it signals input inflation is outpacing management's ability to protect profitability in the near term.
Management's claims vs. what holds up
"Revenue ₹370 Cr, profit ₹38 Cr, +19.2% YoY growth"
"Standalone PAT +31.7% YoY, EBITDA +21.7% YoY" — core business is strong
"Margins between 18-20% targeted" — delivered 17.9%; deflected as cyclical
"Strong momentum in Q1" — but QoQ revenue -0.7%, PAT -10.3%
"Cost management via VAVE and price increases" — partially offsetting; ₹10 Cr jump still evident
What changed on this call
Capex guidance raised sharply: From ₹120 crores (prior annual plan) to ₹270 crores total across the medium term. ₹60 crores already spent, ₹100 crores ordered/in process. The rule of thumb: ₹100 crores capex → ₹130 crores in sales. This is the biggest move, and it signals management is serious about diversification—but it's also a leverage bet that the deployed capex will generate sufficient return.
Portfolio and pipeline expanded: Nominated (lifetime order book) business jumped from ₹800 crores to ₹1,100 crores—a ₹300-crore uplift driven by the GM Corvette win (300,000 units/year peak volume) and other automotive adjacency wins. New ventures launched across 6 verticals: aerospace/defense (via MTR acquisition, ₹25-30 crore order book, targeting ₹300 crore revenue by FY31), industrial bearings (Unitec JV, ₹110 crore investment, ₹130 crore capacity, commissioning April 2027), electrification (Siemens partnership, nascent), data center (R&D stage), and robotics/humanoid components.
Long-term target recalibrated but not formally raised: Prior guidance was ₹2,500 crores by 2031. Management said that's now "too low," cited a 12-month CAGR of 14.38% that extrapolates to ₹2,730 crores by FY31, and called ₹3,000 crores "aspirational" but refused to formalize it. Analysts pressed hard; management deflected to annual updates and cited "conservatism." Translation: internal conviction is uncertain, or macro headwinds make near-term forecasting risky.
The bull-bear ledger
Robust YoY growth (+19.2% revenue, +15.1% PAT) on track with stated targets
Standalone core business explosive: PAT +31.7% YoY, EBITDA +21.7% YoY
Diversification is real and funded: ₹270 Cr capex, M&A executed (MTR), JVs signed (Unitec)
Near-term catalysts concrete: GM Corvette ramp (Q2-Q3), Unitec April 2027, Siemens orders (next 2-3 quarters)
US manufacturing footprint established (Columbia, SC); unlocks OEM wins previously out of reach
Sequential decline not flagged; transparency concern
Operating margin 17.9% misses 18-21% target; reframed rather than owned
Other expenses inflation (₹10 Cr QoQ jump) outpacing VAVE and price offsets
MTR ₹30 Cr order book vs ₹300 Cr FY31 target (90% gap); most deals pre-revenue
Consolidated growth (+15.1%) lags standalone (+31.7%); subsidiary drag evident
Management evasive on formal FY27/FY31 guidance; signals uncertainty
How the street is positioned
The price action tells the story better than any commentary. On the day of the result announcement, NRB's market reaction was +3.63% in delivery (day-1 enthusiasm—the pop). But that pop evaporated. By day 3, it was +0.03% (flat). By day 5, it had reversed to -0.56%, completely erasing the initial gains. The consensus verdict: institutions liked the diversification story at the headline, but as they dug into the sequential decline, margin miss, and guidance opacity, skepticism set in. The stock now sits at ₹458.9, just shy of its all-time high of ₹483 (down 4.99% from ATH) and well above its 52-week low of ₹212.55 (+115.9% off the low). It's above all key SMAs (20, 50, 200); RSI is neutral at 61.8. Volume is increasing, but the price action is cautious accumulation, not conviction.
Ownership has shifted in a mixed way. FII ownership rose from 14.69% (Q4 FY26) to 18.93% (Q1 FY27), a gain of 4.24 percentage points. DII ownership rose from 10.06% to 13.85%, a gain of 3.79 percentage points. So institutional capital is adding. But promoter ownership fell from 51.20% to 44.73%, a loss of 6.47 percentage points. This is a yellow flag. Promoter trim during a capex bet leans toward caution rather than confidence. Bulk block deals in early June show mid-sized traders in the ₹430-438 range, but no clear insider selling pattern.
Risks, ranked by how much they should concern a holder
Input cost inflation outpacing offsets
HIGHOther expenses jumped ₹10 Cr (₹92→₹102) driven by electricity, logistics, petroleum. VAVE and price hikes are offsetting, but if inflation accelerates faster than management can respond, margins will compress below 18-20% for multiple quarters. The ₹10 Cr jump alone is 2.7% of Q1 revenue.
Execution risk on nascent verticals
HIGHMTR aerospace order book is ₹25-30 Cr today but the FY31 target is ₹300 Cr—a ₹270-crore gap that must close in 4 years. Data center is in R&D. Most new verticals are pre-revenue. If execution slips on ramp timelines or order wins don't materialize, the diversification narrative breaks.
Sequential momentum loss not addressed
MEDIUMQoQ revenue -0.7% and PAT -10.3% were not highlighted in opening remarks. If Q2 also shows a QoQ decline, the "strong momentum" claim will erode entirely. This is the near-term credibility test.
Guidance opacity and lack of conviction
MEDIUMManagement refused to formally raise the FY31 target from ₹2,500 Cr to ₹3,000 Cr, instead offering a 12-month CAGR extrapolation. No formal FY27 revenue guidance either. This evasion signals either macro uncertainty or internal doubts about execution.
Consolidated growth lagging standalone
MEDIUMStandalone PAT +31.7% YoY vs consolidated +15.1% implies subsidiaries (SNL, MTR) are dragging. If subsidiary integration fails or drag persists, the group CAGR target will miss and standalone outperformance will look like a one-off.
What to watch next
1 · Q2 FY27 organic run-rate
Does QoQ revenue growth turn positive? Does OPM recover to 18%+? If Q2 shows QoQ stagnation or decline again, the momentum narrative is broken. This is the most important near-term test.
2 · GM Corvette production ramp timing
When does production actually start and at what pace? This is the single biggest near-term revenue catalyst. Delays here directly delay the capex ROI story.
3 · Unitec JV commissioning (April 2027)
Industrial gearbox facility commissioned on schedule? ₹110-crore investment yielding ₹130-crore capacity as promised? This proves capex capability and validates the industrial segment push (currently 14% of revenue, targeting 20-25%).
4 · Siemens electrification orders
Next 2-3 quarters should see material order announcements. Magnitude and timeline matter. Small orders or delays validate the bear thesis; meaningful wins validate the bull thesis.
5 · MTR aerospace order ramp
From ₹30 Cr today toward ₹300 Cr by 2031 requires 10x scaling in 4 years. Sukhoi-30 is a breakthrough (few global competitors), but RFQ pipeline and conversion timing are critical. FY27 contribution is likely minimal; FY28-FY31 will be the real test.
The verdict is Hold, not Buy. NRB has strong fundamentals (YoY growth, diversification, capex commitment) but fragile near-term delivery (sequential decline, margin miss, evasive guidance). Institutional optimism (FII/DII adding) is not yet matched by price conviction (day-5 pop reversal). The number to track from here is adjusted OPM—if margins recover to 18%+ by Q2-Q3 and QoQ growth turns positive, the capex story gains traction and upgrades follow. If OPM stays below 18% and sequential growth remains weak, downgrades are coming. Until the street sees Q2 execution, the risk/reward is balanced, not tilted to the upside. Steady execution on near-term catalysts (Corvette ramp, Unitec commissioning, Siemens orders) will be the proof point.